Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)

This retrospective analysis suggests that using a slow bolus injection with an infusion pump may reduce local adverse reactions following subcutaneous administration of pertuzumab and trastuzumab in patients with HER2-positive breast cancer. The standardized use of infusion pumps could enhance patient comfort, safety, and overall treatment experience.

These findings are particularly relevant to healthcare systems where SC formulations are newly introduced, providing timely evidence to guide patient-centered clinical decision-making. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=637674, identifier CRD42025637674.

P2, N=66, Active, not recruiting, Pfizer | Trial completion date: Nov 2025 --> Jun 2026

Phesgo demonstrated comparable or superior efficacy and favorable safety with markedly improved treatment efficiency in real-world Japanese practice. Phesgo represents a promising alternative to intravenous administration, reducing patient burden and optimizing healthcare resource utilization.

P1, N=150, Not yet recruiting, Biocon Limited

P1, N=312, Recruiting, Genentech, Inc. | Not yet recruiting --> Recruiting

P1, N=312, Not yet recruiting, Genentech, Inc.

The effects of Herceptin or gabapentin, a THBS4 receptor inhibitor, on subcutaneous tumors were examined in nude mice...In vivo, CAFs suppress HER2 expression of subcutaneous GC tumors and induce Herceptin resistance...THBS4 from CAFs downregulated HER2 (ERBB2) expression in GC cells. Thus, THBS4 receptor inhibitors may be useful in preventing the acquisition of resistance to anti-HER2 therapy.

P1/2, N=36, Not yet recruiting, National University Hospital, Singapore | Phase classification: P2 --> P1/2 | Trial primary completion date: Dec 2025 --> Dec 2026

P1, N=76, Recruiting, Daiichi Sankyo | Not yet recruiting --> Recruiting

P1, N=200, Active, not recruiting, Celltrion | Recruiting --> Active, not recruiting

The intravenous formulation (Herceptin) or subcutaneous formulation (Herceptin Hylecta) of the original trastuzumab drug, as well as the biosimilar drugs (Hanquyou) produced in China, showed similar efficacy, while Nab-Paclitaxel demonstrated potential benefits in overall patient. HER2 3+, PD-L1 CPS > 27.5 and HR-negative are independent predictors of pCR. The TCbHP and THP regimens have comparable efficacy, and both are superior to the AC-THP regimen.